By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Sigma Life Science today announced a licensing deal with King's College London for the development and commercialization of technology to identify and validate miRNA targets in research and clinical diagnostics.

The technology was developed at the division of cancer studies at King's College. No further details about the technology or terms of the deal were disclosed.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: mtDNA analysis give glimpse into decline of Neanderthals in Europe, and more.

The University of Arizona's Raina Maier writes that an understanding of the Earth's microbiome is needed.

The proposed Canadian budget emphasizes partnerships with industry, Nature News reports.

An Australian study of personalized medicine has run into problems as it recruits patients.